Xiaolin Wang, Seung‐Jin Kim, Yukun Guan, Richard Parker, Robim M. Rodrigues, Dechun Feng, Shelly C. Lu, Bin Gao – 4 October 2022 – Adipose tissue dysfunction is closely associated with the development and progression of nonalcoholic fatty liver disease (NAFLD). Recent studies have implied an important role of prohibitin‐1 (PHB1) in adipose tissue function. In the current study, we aimed to explore the function of adipocyte PHB1 in the development and progression of NAFLD.

Jie Jiang, Yuandi Ma, Yameng Liu, Dasheng Lu, Xiaoxia Gao, Kristopher W. Krausz, Dhimant Desai, Shantu G. Amin, Andrew D. Patterson, Frank J. Gonzalez, Cen Xie – 4 October 2022 – Nonalcoholic steatohepatitis (NASH) is a rapidly developing pathology around the world, with limited treatment options available. Some farnesoid X receptor (FXR) agonists have been applied in clinical trials for NASH, but side effects such as pruritus and low‐density lipoprotein elevation have been reported. Intestinal FXR is recognized as a promising therapeutic target for metabolic diseases.

Eva Maria Schleicher, Simon Johannes Gairing, Peter Robert Galle, Julia Weinmann‐Menke, Jörn M. Schattenberg, Karel Kostev, Christian Labenz – 3 October 2022 – The Fibrosis‐4 index (FIB‐4) is a recommended noninvasive fibrosis test in patients at risk of liver fibrosis. Chronic liver diseases are often associated with kidney diseases. This study aimed to investigate the association between FIB‐4 and the development of renal failure among the general population.

Jieyun Jiang, Courtney Turpin, Guofang (Shirley) Qiu, Mei Xu, Eun Lee, Terry D. Hinds, Martha L. Peterson, Brett T. Spear – 3 October 2022 – Liver cancer, comprised primarily of hepatocellular carcinoma (HCC), is the third leading cause of cancer deaths worldwide and increasing in Western countries. We previously identified the transcription factor zinc fingers and homeoboxes 2 (Zhx2) as a regulator of hepatic gene expression, and many Zhx2 target genes are dysregulated in HCC. Here, we investigate HCC in Zhx2‐deficient mice using the diethylnitrosamine (DEN)–induced liver tumor model.

Man‐Fung Yuen, Elina Berliba, Wattana Sukeepaisarnjaroen, Sang Hoon Ahn, Tawesak Tanwandee, Young‐Suk Lim, Yoon Jun Kim, Kittiyod Poovorawan, Pisit Tangkijvanich, Christian Schwabe, Timothy Eley, Joanne Brown, Amy C. H. Lee, Emily P. Thi, Bhavna Paratala, Nagraj Mani, Michael J. Sofia, Gaston Picchio, Karen D. Sims, Edward J. Gane – 3 October 2022 – AB‐506 is a potent, pan‐genotypic small molecule capsid inhibitor that inhibits hepatitis B virus (HBV) pregenomic RNA encapsidation.

Steven Balog, Reika Fujiwara, Stephanie Q. Pan, Khairat B. El‐Baradie, Hye Yeon Choi, Sonal Sinha, Qihong Yang, Kinji Asahina, Yibu Chen, Meng Li, Matthew Salomon, Stanley W.‐K. Ng, Hidekazu Tsukamoto – 30 September 2022

Mindie H. Nguyen, Lewis R. Roberts, Nicole M. Engel‐Nitz, Tim Bancroft, A. Burak Ozbay, Amit G. Singal – 29 September 2022 – Suboptimal adherence to guidelines for hepatocellular carcinoma (HCC) surveillance among high‐risk patients is a persistent problem with substantial detriment to patient outcomes. While patients cite cost as a barrier to surveillance receipt, the financial burden they experience due to surveillance has not been examined.

Francesco Vizzutti, Ciro Celsa, Salvatore Battaglia, Roberto Miraglia, Marco Enea, Fabio Marra, Cristian Caporali, Calogero Cammà, Filippo Schepis – 29 September 2022

Jihyun An, Ji‐Hye Oh, Bora Oh, Yoo‐Jin Oh, Jin‐Sung Ju, Wonkyung Kim, Hyo Jung Kang, Chang Ohk Sung, Ju Hyun Shim – 29 September 2022

Melinda Wang, Monika Sarkar, Neil Mehta – 28 September 2022